Skip to main content
  • Original article
  • Open access
  • Published:

Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients

Abstract

Background

Several extrahepatic manifestations have been reported and mixed cryoglobulinemia is a clonal disorder of B cells which is strongly associated with hepatitis C virus (HCV).

New regimens of direct-acting antiviral agents (DAAs) have recently been approved for the treatment of genotype 4 HCV which offer improved results of sustained virologic response (SVR) in the treatment-naive and previously treated patients.

Aim

To assess the prevalence of cryoglobulinemia for evaluating the efficacy of DAA therapy on it.

Patients and methods

Patients received one of the following regimens: sofosbuvir, daclatasvir±ribavirin, or sofosbuvir plus ledipasvir±ribavirin follow-up for 24 weeks after treatment.

Results

A total of 132 patients were involved in our study: 65 men and 67 women. Cryocrit-positive patients clinically presented with clinical manifestations in 32 (53.3%) patients out of the 60 patients. After 12 weeks of DAAs treatment, there was a significant reduction in cryoprecipitate level and rheumatoid factor (RF) level with improvement of glomerular filtration rate, basal C4, and clinical improvement of purpura, Raynaud’s phenomenon, and this was the same when 38 patients continued treatment for 24 weeks. However, comparing 12 and 24-week therapy showed significant improved difference in cryoprecipitate level but improved glomerular filtration rate, basal C4, and decreased level of RF, proteinuria, purpura, and peripheral neuropathy although it did not reach statistical significance

Conclusion

Cryocrit-positive patients were old age, cirrhotics with long duration of HCV. There is significant improvement of both laboratory and clinical parameters of cryoglobulinemia after SVR12 and more significant after SVR24. There is no significant difference in using different DDA regimen with or without ribavirin on the SVR at either 12 or 24 weeks. So, we advise basal laboratory and clinical parameters of mixed cryoglobulinemia before designing treatment regimens of HCV patients in Egypt.

References

  1. Averhoff FM, Glass N, Holtman D. Global burden of hepatitis C considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55:510–515.

    Article  Google Scholar 

  2. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a national survey. J Viral Hepat 2012; 19:560–567.

    Article  CAS  Google Scholar 

  3. Agnello V. The aetiology of mixed cryoglobulinaemia associated with hepatitis C virus infection. Scand J Immunol 1995; 42:179–184.

    Article  CAS  Google Scholar 

  4. Romitelli F, Paolo Pucillo L, Basile U, Stasio E. Comparison between the traditional and a rapid screening test for cryoimmunoglobulins detection. Biomed Res Int 2015; 2015:783063.

    Article  Google Scholar 

  5. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119:1745–1754.

    Article  CAS  Google Scholar 

  6. Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54:1250–1262.

    Article  Google Scholar 

  7. Centers for Disease Control and Prevention (CDC). Progress toward prevention and control of hepatitis C virus infection- Egypt, 2001–2012. MMWR Morb Mortal Wkly Rep 2012; 61:545–549.

    Google Scholar 

  8. Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol 2014; 109:628–635.

    Article  CAS  Google Scholar 

  9. Urraro T, Gragnani L, Piluso A, Fabbrizzi A, Monti M, Fognani E, et al. Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. Case Reports Immunol 2015; 2015:816424.

    Article  Google Scholar 

  10. European Association for Study of Liver. EASL 2015 recommendations on treatment of hepatitis C 2015. J Hepatol 63:199–236.

  11. Shiha G, Seif S, Maher M, Etreby S, Zalata K. Comparison between transient elastography (Fibroscan) and liver biopsy for the diagnosis of hepatic fibrosis in chronic hepatitis genotype 4. Egypt Liver J 2014; 4:106–111.

    Article  Google Scholar 

  12. Santagostino E, Colombo M, Cultraro D, Muc¸a-Perja M, Gringeri A, Mannucci PM. High prevalence of serum cryoglobulins in multitransfused hemophilic patients with chronic hepatitis C. Blood 1998; 92:516–519.

    Article  CAS  Google Scholar 

  13. Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 2016; 63:408–417.

    Article  CAS  Google Scholar 

  14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604–612.

    Article  Google Scholar 

  15. Cacoub P, Comarmond C, Domont F, et al. Cryoglobulinemia vasculitis. Am J Med 2015; 128:950–955.

    Article  Google Scholar 

  16. Pawlotsky JM, Aghemo A, Back D, et al. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63:199–236.

    Google Scholar 

  17. Saadoun D, Resche Rigon M, Pol S, Thibault V, Blanc F, Pialoux G, et al. PegIFNα/ribavirin/ protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 2015; 62:24–30.

    Article  CAS  Google Scholar 

  18. Roccatello D, Sciascia S, Rossi D, Solfietti l, et al. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Oncotarget 2017; 8:41764–41777.

    Article  Google Scholar 

  19. Emery JS, Kuczynski M, La D, et al. Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia. Am J Gastroenterol 2017; 112:1298–1308.

    Article  CAS  Google Scholar 

  20. Hassan AM, Osman HA, Mahmoud HS, Hassan MH, Hashim AA, Ameen HH. Sofosbuvir-daclatasvir improves hepatitis C virus-induced mixed cryoglobulinemia: Upper Egypt experience. Infect Drug Resist 2018; 11:895–901.

    Article  CAS  Google Scholar 

  21. Gragnani L, Fognani E, Piluso A, et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, openlabel, cohort study. Hepatology 2015; 61:1145–1153.

    Article  CAS  Google Scholar 

  22. Saadoun D, Pol S, Ferfar Y, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology 2017; 153:49–52.e5.

    Article  CAS  Google Scholar 

  23. Martin P, Fabrizi F. Benefit of direct-acting antiviral therapy for cryoglobulinemia due to hepatitis C infection. Am J Gastroenterol 2017; 112:1309–1310.

    Article  Google Scholar 

  24. Sollima S, Milazzo L, Peri AM, Torre A, Antinori S, Galli M. Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology (Oxford) 2016; 55:2084–2085.

    Article  Google Scholar 

  25. Cornella SL, Stine JG, Kelly V, Caldwell SH, Shah NL. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series. Postgrad Med 2015; 127:413–417.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Amr M. Elrabat.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elshazly, T.A., Elrabat, A.M., Ali, S.A.M. et al. Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients. Egypt J Intern Med 31, 458–464 (2019). https://doi.org/10.4103/ejim.ejim_41_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_41_19

Keywords